The major goal of this study is to conduct a prospective, longitudinal study of autoimmune PAP to examine outcome measures for disease severity of potential use in clinical practice and/or clinical research studies. These results will impact the field by: 1) improving an understanding of the clinical course of autoimmune PAP, 2) providing information on various clinical outcome and quality of life outcome measures to guide patients and physicians in making treatment choices, and 3) facilitate the development of pharmaco-therapeutics for autoimmune PAP and 4) better informing PAP researchers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Longitudinal evaluation of GM-CSF autoantibody levels
Timeframe: Baseline, 1 year, and 2 years
Longitudinal evaluation of the maximal phospho-STAT5 level after GM-CSF stimulation
Timeframe: Baseline, 1 year, and 2 years
Longitudinal evaluation of the STAT5 Phosphorylation Index
Timeframe: Baseline, 1 year, and 2 years
Longitudinal evaluation of the GM-CSF Signaling Index
Timeframe: Baseline, 1 year, and 2 years
Longitudinal evaluation of the dose GM-CSF to stimulation 1/2 maximal STAT5 phosphorylation (EC50)
Timeframe: Baseline, 1 year, and 2 years